Product/Composition:- | Sitagliptin + Metformin tablets |
---|---|
Strength:- | 50/500 mg, 50/850 mg, 50/1000 mg |
Form:- | Tablets |
Reference Brands:- | Janumet (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sitagliptin + Metformin combines DPP-4 inhibition with insulin sensitization. Sitagliptin boosts incretin hormones, enhancing insulin release and reducing glucagon. Metformin decreases hepatic glucose production and improves peripheral glucose uptake. This dual mechanism provides superior glycemic control, lowers HbA1c, and minimizes hypoglycemia risk—ideal for managing Type 2 diabetes effectively.
Sitagliptin + Metformin tablets are FDA-approved in the USA and EMA-authorized in the EU for managing type 2 diabetes. These fixed-dose combination tablets comply with GMP standards and serve as adjuncts to diet and exercise. Marketed under brands like Janumet®, they require regulatory labeling for risks like lactic acidosis and renal impairment. Pharmacovigilance is mandatory in both regions. Manufacturers must adhere to 21 CFR (USA) and EMA Modules 1–5 (EU). For regulatory support, sourcing, or B2B pharma solutions, visit PharmaTradz.com — your global partner in compliant pharmaceutical trade.